OBJECTIVE: Use of recombinant human bone morphogenetic protein-2 (rhBMP-2) is becoming a common clinical approach to enhance bone repair. There is little or no information in the literature on the dose of rhBMP-2 required for effective healing of critical-sized defects such as those associated with trauma. In this study, we used a segmental defect model to assess the dose response of rhBMP-2 using quantitative and qualitative endpoints. METHODS: Femoral defects in rats were replaced with absorbable collagen sponges carrying rhBMP-2 (0, 1, 5, 10 or 20 μg; N=5). At 4-weeks new bone formation was assessed using quantitative (radiography and microcomputed tomography) and qualitative (histology and backscattered-SEM) endpoints statistically compared. RESULTS: rhBMP-2 showed increased bridging in the gap. Quantitative evaluation presented a bi-phasic dose response curve. Histological assessment revealed that with rhBMP-2 the defect showed the presence of spongy bone with the trabeculae layered with active osteoblasts and osteoclasts. The density and compactness of the bone varied with the dose of rhBMP-2. CONCLUSIONS: Our findings revealed that all doses of rhBMP-2 result in new bone formation. However, there is an optimum dose of 12 μg of rhBMP-2 for bone repair in this model, above which and below which less stimulation of bone occurs.
OBJECTIVE: Use of recombinant humanbone morphogenetic protein-2 (rhBMP-2) is becoming a common clinical approach to enhance bone repair. There is little or no information in the literature on the dose of rhBMP-2 required for effective healing of critical-sized defects such as those associated with trauma. In this study, we used a segmental defect model to assess the dose response of rhBMP-2 using quantitative and qualitative endpoints. METHODS:Femoral defects in rats were replaced with absorbable collagen sponges carrying rhBMP-2 (0, 1, 5, 10 or 20 μg; N=5). At 4-weeks new bone formation was assessed using quantitative (radiography and microcomputed tomography) and qualitative (histology and backscattered-SEM) endpoints statistically compared. RESULTS: rhBMP-2 showed increased bridging in the gap. Quantitative evaluation presented a bi-phasic dose response curve. Histological assessment revealed that with rhBMP-2 the defect showed the presence of spongy bone with the trabeculae layered with active osteoblasts and osteoclasts. The density and compactness of the bone varied with the dose of rhBMP-2. CONCLUSIONS: Our findings revealed that all doses of rhBMP-2 result in new bone formation. However, there is an optimum dose of 12 μg of rhBMP-2 for bone repair in this model, above which and below which less stimulation of bone occurs.
Authors: Nick J Willett; Mon-Tzu A Li; Brent A Uhrig; Joel David Boerckel; Nathaniel Huebsch; Taran L Lundgren; Gordon L Warren; Robert E Guldberg Journal: Tissue Eng Part C Methods Date: 2012-11-02 Impact factor: 3.056
Authors: Lauren B Priddy; Laxminarayanan Krishnan; Marian H Hettiaratchi; Sukhita Karthikeyakannan; Nikhil Gupte; Robert E Guldberg Journal: J Orthop Res Date: 2022-03-27 Impact factor: 3.102
Authors: Laxminarayanan Krishnan; Lauren B Priddy; Camden Esancy; Mon-Tzu Alice Li; Hazel Y Stevens; Xi Jiang; Lisa Tran; David W Rowe; Robert E Guldberg Journal: Clin Orthop Relat Res Date: 2015-09 Impact factor: 4.176
Authors: Tamer Al Kayal; Daniele Panetta; Barbara Canciani; Paola Losi; Maria Tripodi; Silvia Burchielli; Priscilla Ottoni; Piero Antonio Salvadori; Giorgio Soldani Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Michelle T Poldervaart; Huanan Wang; Johan van der Stok; Harrie Weinans; Sander C G Leeuwenburgh; F Cumhur Öner; Wouter J A Dhert; Jacqueline Alblas Journal: PLoS One Date: 2013-08-19 Impact factor: 3.240